Specifically, immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, reinstate the immune system’s capacity to identify tumors by obstructing the pathways utilized by tumor cells to evade immune surveillance. Here, PDCD1 is linked to neoplasm.